Global DNA Damage Response Drugs Market

1
Global DNA Damage Response Drugs
Market
Focus on Commercialized Drugs, Potential
Pipeline Drugs, Application, Country Data (13
Countries), and Competitive Landscape Analysis
and Forecast 2020-2030 August 2020 TOC
2
Global DNA Damage Response Drugs Market
BIS Research is a leading market intelligence and
technology research company. BIS Research
publishes in-depth market intelligence reports
focusing on the market estimations, technology
analysis, emerging high-growth applications,
deeply segmented granular country-level market
data and other important market parameters
useful in the strategic decision making for
senior management. BIS Research provides
multi-client reports, company profiles,
databases, and custom research services.
Copyright 2020 BIS Research All Rights
Reserved. This document contains highly
confidential information and is the sole
property of BIS Research. Disclosing, copying,
circulating, quoting or otherwise reproducing any
or all contents of this document is strictly
prohibited. Access to this information is
provided exclusively for the benefit of the
people or organization concerned. It may not be
accessed by, or offered whether for sale or
otherwise to any third party.
3
Global DNA Damage Response Drugs Market
Table of Contents
Product Definition ...............................
..................................................
.............32 1.1 Inclusion and Exclusion
..................................................
............................ 32
1.
Research Scope....................................
..................................................
............33 2.1 Scope of the
Study.............................................
..........................................
33 2.2 Key Questions Answered in the Report
..................................................
... 34
2.
Research Methodology .............................
..................................................
.......36 3.1 DNA Damage Response Drugs in
Oncology Research Methodology....................
..................................................
........................... 36 3.2 Data Sources
..................................................
.............................................. 37
3.
3.2.1 3.2.2
Primary Data Sources .............................
..........................................
37 Secondary Data Sources ........................
.......................................... 38
3.3 Market Estimation Model ......................
..................................................
..... 39
Market Overview ..................................
..................................................
.............42 4.1 Introduction
..................................................
................................................
42 4.2 Importance of DDR Pathways in
Oncology..........................................
...... 42 4.3 Key Strategies for Targeting DDR
Pathways .........................................
.... 43 4.4 DDR Drugs Commercialization
Landscape.........................................
....... 45 4.5 COVID-19 Impact on Oncology
Clinical Research ................................
.... 46 4.6 Market Size and Growth Potential,
Million, 2019-2030 ............................
47
4.
4.6.1 4.6.2 4.6.3 4.6.4 4.6.5
North America.....................................
...............................................
47 Europe ........................................
..................................................
...... 48 Asia-Pacific (APAC).....................
..................................................
.... 49 Latin America (LATAM) ....................
.................................................
50 Rest-of-the-World (RoW)........................
........................................... 51
Industry Insights.................................
..................................................
..............52 5.1 Overview ....................
..................................................
................................. 52 5.2 Legal
Requirements and Frameworks in the U.S.
..................................... 52
5.2.1 Clinical Trial Authorization
..................................................
............. 52
5.
4
Global DNA Damage Response Drugs Market
5.2.2 5.2.3
Marketing Authorization ..........................
.........................................
52 Post-Authorization Regulations
..................................................
..... 55
5.3 Legal Requirements and Frameworks in Europe
...................................... 55
5.3.1 5.3.2 5.3.3 5.3.4
Centralized Procedure ............................
..........................................
56 Decentralized Procedure .......................
...........................................
56 Mutual-Recognition Procedure
..................................................
...... 56 National Procedure......................
..................................................
.... 57
5.4 Legal Requirements and Frameworks in
Asia-Pacific .............................. 57
5.4.1 5.4.2
China ............................................
..................................................
.... 57 Japan ....................................
..................................................
............ 58
5.5 Patent Analysis ..............................
..................................................
............ 59
Market Dynamics ..................................
..................................................
............61 6.1 Overview ......................
..................................................
............................... 61 6.2 Impact
Analysis .........................................
..................................................
. 61 6.3 Market Drivers ..........................
..................................................
.................. 62
6.
6.3.1 6.3.2 6.3.3 6.3.4
Rising Global Prevalence of Cancer
................................................
62 Favorable Regulatory Environment
.................................................
63 Increasing Oncology RD Expenditure............
............................... 64 Increase in
Adoption of Precision Medicine in
Cancer Treatment .................................
..................................................
........ 66
6.4 Market Restraints ............................
..................................................
........... 67
6.4.1 6.4.2 6.4.3
High Cost Hindering the Adoption Rate
..........................................
67 Unfavorable Reimbursement Scenario.............
............................... 67 Safety
Concerns Pertaining to Severe Adverse
Effects................. 68
6.5 Market Opportunity ...........................
..................................................
......... 69 6.5.1 Massive scope in Emerging
Regions ..........................................
.... 69
Competitive Landscape ............................
..................................................
.......70 7.1 Key Strategies and Developments
..................................................
........... 70
7.
7.1.1 7.1.2 7.1.3
Product Approvals and Other Activities............
.............................. 71 Synergistic
Activities .......................................
................................. 72 Product
Launch and Updradations...........................
....................... 73
5
Global DNA Damage Response Drugs Market
7.1.4 7.1.5
Business Expansion and Funding ...................
................................ 74 Mergers and
Acquisitions......................................
........................... 75
7.2 Market Share Analysis, 2018-2019..............
................................................
76 7.3 Growth Share Analysis .....................
..................................................
......... 78
8.
Epidemiology Analysis for DNA Damage Response
Drugs............................80
Clinical Landscape ...............................
..................................................
............86 9.1 By Phase of Development
..................................................
......................... 86 9.2 By DDR Pathway
Target ...........................................
................................... 87 9.3 By
Oncology Specialty ...............................
.................................................
88
9.

• Global DNA Damage Response Drugs Market, by
  Commercialized Drugs (Million),
  2019-2030.........................................
  ..................................................
  89
• 10.1 Overview ....................................
  ..................................................
  ................. 89
• 10.2 Lynparza ....................................
  ..................................................
  ................. 90
• 10.3 Talzenna.....................................
  ..................................................
  ................. 93
• 10.4 Zejula.......................................
  ..................................................
  .................... 95
• 10.5 Rubraca......................................
  ..................................................
  ................. 98
• DNA Damage Response Drugs, by Potential Pipeline
  Drugs .......................101 11.1 Overview
  ..................................................
  ..................................................
  . 101 11.2 PARP Inhibitor........................
  ..................................................
  .................. 101 11.2.1 Phase
  III...............................................
  ............................................. 102
• 11.2.1.1 Pamiparib ...............................
  ..................................................
  ......... 102
• 11.2.1.2 Veliparib ...............................
  ..................................................
  ........... 103
• 11.2.1.3 Fluzoparib...............................
  ..................................................
  ......... 104
• 11.2.2 Phase II...................................
  ..................................................
  ........ 106
• 11.2.3 Phase I....................................
  ..................................................
  ........ 106
• 11.3 WEE1 Kinase Inhibitor .......................
  ..................................................
  ...... 107
• 11.3.1 Phase I....................................
  ..................................................
  ........ 107
• 11.4 ATR Kinase Inhibitor.........................
  ..................................................
  ....... 108
• 11.4.1 Phase II...................................
  ..................................................
  ........ 108

6
Global DNA Damage Response Drugs Market

• 11.4.2 Phase I....................................
  ..................................................
  ........ 108
• 11.5 Aurora B Kinase Inhibitor....................
  ..................................................
  .... 109
• 11.5.1 Phase II...................................
  ..................................................
  ........ 109
• 11.6 DNA-PK Inhibitors ...........................
  ..................................................
  ......... 109
• 11.6.1 Phase II...................................
  ..................................................
  ........ 110
• 11.6.2 Phase I....................................
  ..................................................
  ........ 110
• 11.7 Others.......................................
  ..................................................
  ................. 110
• 11.7.1 Phase II...................................
  ..................................................
  ........ 111
• 11.7.2 Phase I....................................
  ..................................................
  ........ 111
• Global DNA Damage Response Drugs Market, by
  Application, (Million), 2019-2030
  ..................................................
  ..................................................
  ......112
• 12.1 Overview ....................................
  ..................................................
  ............... 112
• 12.2 Ovarian Cancer...............................
  ..................................................
  .......... 113
• 12.3 Breast Cancer................................
  ..................................................
  ........... 118
• 12.4 Pancreatic Cancer ...........................
  ..................................................
  ......... 121
• 12.5 Prostate Cancer..............................
  ..................................................
  .......... 123
• Global DNA Damage Response Drugs Market, by
  Region (Million), 2019- 2030 ...................
  ..................................................
  ..............................................126
• 13.1 Overview ....................................
  ..................................................
  ............... 126
• 13.2 North America ...............................
  ..................................................
  ........... 129
• 13.2.1 U.S. ......................................
  ..................................................
  ........... 132

7
Global DNA Damage Response Drugs Market
13.4 Asia-Pacific.................................
..................................................
.............. 149 13.4.1 China
..................................................
..............................................
152 13.4.2 Japan .................................
..................................................
............. 153 13.4.3 India ...................
..................................................
............................. 155 13.4.4 Australia
.................................................
..........................................
156 13.4.5 Rest-of-APAC...........................
..................................................
...... 158 13.5 Latin America ....................
..................................................
....................... 159 13.5.1 Brazil.........
..................................................
......................................
161 13.5.2 Rest-of-Latin America
..................................................
................... 163 13.6 Rest-of-the-World
..................................................
.....................................
164 14. Company Profiles .........................
..................................................
..................165 14.1 Overview
..................................................
..................................................
. 165 14.2 AbbVie Inc.............................
..................................................
.................... 166 14.2.1 Company Overview
..................................................
....................... 166 14.2.2 Role of AbbVie
Inc. in Global DNA Damage Response Drugs
Market............................................
..................................................
. 166 14.2.3 Financials ..........................
..................................................
............. 168 14.2.4 Key Insights about
Financial Health of the Company
.................. 170 14.2.5 SWOT Analysis
..................................................
.............................. 171
14.3 AstraZeneca plc .............................
..................................................
.......... 172 14.3.1 Company Overview
..................................................
....................... 172 14.3.2 Role of
AstraZeneca plc in Global DNA Damage
Response Drugs Market ............................
..................................................
..... 172 14.3.3 Financials ......................
..................................................
................. 176 14.3.4 Key Insights about
Financial Health of the Company
.................. 178 14.3.5 SWOT Analysis
..................................................
.............................. 179 14.4 Bayer
AG................................................
..................................................
... 180 14.4.1 Company Overview
..................................................
....................... 180 14.4.2 Role of Bayer
AG in Global DNA Damage Response
Drugs Market......................................
..................................................
....... 180 14.4.3 Financials ....................
..................................................
................... 181 14.4.4 Key Insight about
Financial Health of the Company
.................... 184
8
Global DNA Damage Response Drugs Market
14.4.5 SWOT Analysis .............................
..................................................
. 185 14.5 BeiGene, Ltd. .........................
..................................................
................... 186 14.5.1 Company Overview
..................................................
....................... 186 14.5.2 Role of
BeiGene, Ltd. in Global DNA Damage Response Drugs
Market ...........................................
........................................
186 14.5.3 Financials ............................
..................................................
........... 188 14.5.4 Key Insights about
Financial Health of the Company
.................. 190 14.5.5 SWOT Analysis
..................................................
.............................. 191 14.6 Clovis
Oncology..........................................
...............................................
192 14.6.1 Company Overview ....................
..................................................
... 192 14.6.2 Role of Clovis Oncology in Global
DNA Damage Response Drugs Market
..................................................
.................................
192 14.6.3 Financials ............................
..................................................
........... 194 14.6.4 Key Insights about
Financial Health of the Company
.................. 195 14.6.5 SWOT Analysis
..................................................
.............................. 196
14.7 Debiopharm International SA..................
..................................................
197 14.7.1 Company Overview ...................
..................................................
.... 197 14.7.2 Role of Debiopharm International
SA in Global DNA Damage Response Drugs Market
..................................................
............... 197 14.7.3 SWOT Analysis
..................................................
.............................. 199 14.8 Eli Lilly
Company.........................................
...........................................
200 14.8.1 Company Overview ......................
..................................................
. 200 14.8.2 Role of Eli Lilly Company in
Global DNA Damage Response Drugs Market
..................................................
............... 200 14.8.3 Financials
..................................................
.......................................
201 14.8.4 Key Insights about Financial Health
of the Company .................. 203
14.8.5 SWOT Analysis ............................
..................................................
.. 204 14.9 GlaxoSmithKline plc
..................................................
................................ 205
14.9.1 Company Overview .........................
................................................
205 14.9.2 Role of GlaxoSmithKline plc in Global
DNA Damage Response Drugs Market
..................................................
............... 205 14.9.3 Financials
..................................................
.......................................
207 14.9.4 Key Insights about Financial Health of
the Company .................. 209
9
Global DNA Damage Response Drugs Market
14.9.5 SWOT Analysis .............................
..................................................
. 210 14.10 Merck KGaA...........................
..................................................
................... 211 14.10.1 Company Overview
..................................................
....................... 211 14.10.2 Role of Merck
KGaA in Global DNA Damage Response Drugs Market
..................................................
.................................
211 14.10.3 Financials ...........................
..................................................
............ 213 14.10.4 Key Insights about
Financial Health of the Company
.................. 215 14.10.5 SWOT Analysis
..................................................
.............................. 216 14.11 NMS
Group S.p.A ......................................
.................................................
217 14.11.1 Company Overview ....................
..................................................
... 217 14.11.2 Role of NMS Group S.p.A in Global
DNA Damage Response Drugs Market
..................................................
.................................
217 14.11.3 SWOT Analysis ........................
..................................................
...... 219 14.12 Onxeo SA ........................
..................................................
.......................... 220 14.12.1 Company
Overview .........................................
................................ 220 14.12.2 Role
of Onxeo SA in Global DNA Damage Response
Drugs Market......................................
..................................................
....... 220 14.12.3 Financials ...................
..................................................
.................... 222 14.12.4 Key Insights
about Financial Health of the Company
.................. 224 14.12.5 SWOT Analysis
..................................................
.............................. 225 14.13 Pfizer
Inc. .............................................
..................................................
..... 226 14.13.1 Company Overview
..................................................
....................... 226 14.13.2 Role of
Pfizer Inc. in Global DNA Damage Response
Drugs Market......................................
..................................................
....... 226 14.13.3 Financials ...................
..................................................
.................... 228 14.13.4 Key Insights
about Financial Health of the Company
.................. 232 14.13.5 SWOT Analysis
..................................................
.............................. 233 14.14 Repare
Therapeutics......................................
............................................ 234
14.14.1 Company Overview .........................
................................................
234 14.14.2 Role of Repare Therapeutics in Global
DNA Damage Response Drugs Market
..................................................
............... 234 14.14.3 SWOT Analysis
..................................................
.............................. 236 14.15 Sierra
Oncology, Inc. ...................................
.............................................. 237
10
Global DNA Damage Response Drugs Market
14.15.1 Company Overview .........................
................................................
237 14.15.2 Role of Sierra Oncology, Inc. in
Global DNA Damage Response Drugs Market
..................................................
............... 237 14.15.3 Financials
..................................................
.......................................
239 14.15.4 Key Insights about Financial Health
of the Company .................. 240
14.15.5 SWOT Analysis ............................
..................................................
.. 241 14.16 Zentalis Pharmaceuticals, LLC
..................................................
............... 242 14.16.1 Company Overview
..................................................
....................... 242 14.16.2 Role of
Zentalis Pharmaceuticals, LLC in Global
DNA Damage Response Drugs Market..................
.................................
242 14.16.3 SWOT Analysis ........................
..................................................
...... 244
11
Global DNA Damage Response Drugs Market
List of Figures Figure 1 Global Prevalence of
Prostate and Breast Cancer, 2012-2017.............
............................ 21 Figure 2 Steps
for Obtaining Marketing Authorization in the U.S.
..................................................
. 22 Figure 3 Clinical Landscape of DNA Damage
Response Drugs, by Phase of Development
.......... 23 Figure 4 Clinical Landscape of
DNA Damage Response Drugs, by Pathway Target
..................... 24 Figure 5 Implications
of COVID-19 on Cancer Clinical Trials Short- and
Long-Term Implications............................
..................................................
............................................
25 Figure 6 Global Target Population of DNA
Damage Response Drugs, 2020-2030..................
....... 26 Figure 7 Impact Analysis of Market
Drivers and Market Challenges on the Global
DNA Damage Response Drugs Market..................
..................................................
.................... 27 Figure 8 Global DNA
Damage Response Drugs Market, by Commercialized
Drugs, 2019 vs. 2030 (Million)...................
..................................................
...........................................
28 Figure 9 Expected Revenue of DNA Damage
Response Drugs, by Potential Pipeline Drugs, 2025
vs. 2030 .........................................
..................................................
........................... 29 Figure 10 Global
DNA Damage Response Drugs Market, by Application,
2019 vs. 2030 (Million) .........................
..................................................
..................................................
. 30 Figure 11 Global DNA Damage Response Drugs
Market Snapshot...................................
............ 31 Figure 2.1 Global DNA Damage
Response Drugs Market Segmentation................
....................... 33 Figure 3.1 Global DNA
Damage Response Drugs Market Research
Methodology ....................... 36 Figure
3.2 Bottom-up Approach (Segment-Wise
Analysis).........................................
.................... 39 Figure 3.3 Top-Down
Approach (Segment-Wise Analysis)..................
...........................................
40 Figure 4.1 Underlying Pathway of DNA Damage
and Repair .......................................
.................. 43 Figure 4.2 Implications
of COVID-19 on Cancer Clinical Trials Short- and
Long-Term Implications............................
..................................................
............................................
47 Figure 4.3 North America DNA Damage Response
Drugs Market, 2019 and 2030.......................
. 48 Figure 4.4 Europe DNA Damage Response
Drugs Market, 2019-2030 ..........................
............... 49 Figure 4.5 Asia-Pacific DNA
Damage Response Drugs Market, 2019-2030
.................................. 50 Figure 4.6
Latin America DNA Damage Response Drugs Market,
2019-2030 ............................... 51
Figure 5.1 Steps for Obtaining Marketing
Authorization.....................................
............................. 53 Figure 5.2
Share of Patents (by Ownership), 2016-2019
..................................................
.............. 60
12
Global DNA Damage Response Drugs Market
Figure 6.1 Global Prevalence of Breast,
Prostate, and Ovarian Cancer, 2013-2017
...................... 62 Figure 7.1 Share of
Key Developments and Strategies, January 2016
May 2020 ....................... 71 Figure 7.2
Product Approvals and Other Activities Share (by
Company), January 2016 May 2020.................
..................................................
..................................................
........ 72 Figure 7.3 Synergistic Activities
Share (by Company), January 2016 May 2020
......................... 73 Figure 7.4 Product
Launch and Upgradations Share (by Company),
January 2016 May 2020...........................
..................................................
..................................................
...... 74 Figure 7.5 Business Expansion and
Funding Share (by Company), January 2016 May
2020..............................................
..................................................
..................................... 75 Figure
7.6 Mergers and Acquisitions Share (by Company),
January 2016 May 2020 ................. 76
Figure 7.7 Market Share Analysis for Global DNA
Damage Response Drugs Market, 2018 and
2019..............................................
..................................................
.............................. 77 Figure 7.8
Growth-Share Analysis for Global DNA Damage
Response Drugs Market, (by Companies), 2019
..................................................
..................................................
........... 78 Figure 8.1 Global Prevalence of
Ovarian Cancer (2012-2017) .......................
................................ 81 Figure 8.2
Global Prevalence of Breast Cancer (2012-2017)
..................................................
....... 81 Figure 8.3 Global Prevalence of
Prostate Cancer (2012-2017) ......................
................................ 82 Figure 8.4
Global Prevalence of Pancreatic Cancer
(2012-2017).......................................
............ 82 Figure 8.5 Global Target
Population of Ovarian Cancer (2020-2030)
.............................................
83 Figure 8.6 Global Target Population of Breast
Cancer (2020-2030) ...............................
................ 84 Figure 8.7 Global Target
Population of Pancreatic Cancer
(2020-2030).......................................
.. 84 Figure 8.8 Global Target Population of
Prostate Cancer (2020-2030) ......................
...................... 85 Figure 9.1 DNA Damage
Response Drugs Developmental Phases
..............................................
86 Figure 9.2 DNA Damage Response Drugs, by
Pathway Target ...................................
.................. 87 Figure 9.3 DNA Damage
Response Drugs by Oncology Specialty.............
................................... 88 Figure
10.1 Global DNA Damage Response Drugs Market, by
Commercialized Drugs, 2019-2030
..................................................
..................................................
....................... 89 Figure 10.2 Global
Revenue for Lynparza, 2019-2030
..................................................
................. 91 Figure 10.3 Treatment Flow
of Lynparza for Each Indication...................
....................................... 92 Figure
10.4 Global Revenue for Talzenna, 2019-2030
..................................................
................. 93 Figure 10.5 Treatment Flow
of Talzenna for Each Indication...................
....................................... 94
13
Global DNA Damage Response Drugs Market
Figure 10.6 Global Revenue for Zejula, 2019-2030
..................................................
...................... 96 Figure 10.7 Treatment
Plan of Zejula for Each Indication
..................................................
............. 97 Figure 10.8 Global Revenue for
Rubraca, 2019-2030 ...............................
..................................... 98 Figure
10.9 Treatment Plan of Rubraca for Each
Indication .......................................
.................... 99 Figure 11.1 Expected
Revenue for Pamiparib (by Late Phase), 2025-2030
................................. 103 Figure
11.2 Expected Revenue for Veliparib (by Late
Phase), 2025-2030 ................................
... 104 Figure 11.3 Expected Revenue for
Fluzoparib (by Late Phase), 2025-2030.............
.................... 105 Figure 12.1 Global DNA
Damage Response Drugs Market (by Application)
................................ 112 Figure
12.2 Global DNA Damage Response Drugs Market (by
Application), 2019-2030 ............. 113 Figure
12.3 Global DNA Damage Response Drugs Market (by
Ovarian Cancer), 2019-2030...... 114 Figure
12.4 Global DNA Damage Response Drugs Market (by
Breast Cancer), 2019-2030........ 118 Figure
12.5 Global DNA Damage Response Drugs Market (by
Pancreatic Cancer), 2019- 2030...................
..................................................
..................................................
............ 121 Figure 12.6 Global DNA Damage
Response Drugs Market (by Prostate Cancer), 2019-
2030.............................................
..................................................
.................................... 123 Figure
13.1 Global DNA Damage Response Drugs Market
Snapshot (by Region) ...................... 126
Figure 13.2 Global DNA Damage Response Drugs
Market (by Region), 2019-2030 ...................
127 Figure 13.3 Global DNA Damage Response
Drugs Market Share (by Region), 2019
and 2030..........................................
..................................................
.......................................
128 Figure 13.4 North America DNA Damage
Response Drugs Market, 2019-2030
.......................... 130 Figure 13.5
North America Market Dynamics ...................
..................................................
......... 131 Figure 13.6 North America DNA
Damage Response Drugs Market (by Country),
2019-2030...... 131 Figure 13.7 U.S. DNA Damage
Response Drugs Market, 2019-2030
..........................................
133 Figure 13.8 Canada DNA Damage Response Drugs
Market, 2019-2030 ................................
.... 135 Figure 13.9 Europe DNA Damage Response
Drugs Market, 2019-2030 ..........................
........... 136 Figure 13.10 Europe Market
Dynamics..........................................
...............................................
137 Figure 13.11 Europe DNA Damage Response
Drugs Market (by Country), 2019-2030
............... 138 Figure 13.12 Germany DNA
Damage Response Drugs Market, 2019-2030
................................ 139 Figure
13.13 France DNA Damage Response Drugs Market,
2019-2030....................................
141 Figure 13.14 U.K. DNA Damage Response Drugs
Market, 2019-2030 ................................
........ 142 Figure 13.15 Italy DNA Damage
Response Drugs Market, 2019-2030..................
....................... 144
14
Global DNA Damage Response Drugs Market
Figure 13.16 Spain DNA Damage Response Drugs
Market, 2019-2030.................................
..... 145 Figure 13.17 Switzerland DNA Damage
Response Drugs Market, 2019-2030..................
........... 147 Figure 13.18 Rest-of-Europe DNA
Damage Response Drugs Market, 2019-2030...........
............ 148 Figure 13.19 Asia-Pacific DNA
Damage Response Drugs Market, 2019-2030
............................ 149 Figure 13.20
APAC Market Dynamics ............................
..................................................
........... 150 Figure 13.21 APAC DNA Damage
Response Drugs Market (by Country),
2019-2030................. 151 Figure 13.22
China DNA Damage Response Drugs Market,
2019-2030......................................
152 Figure 13.23 Japan DNA Damage Response Drugs
Market, 2019-2030 ................................
..... 154 Figure 13.24 India DNA Damage Response
Drugs Market, 2019-2030 ..........................
............. 155 Figure 13.25 Australia DNA
Damage Response Drugs Market, 2019-2030
................................. 157 Figure
13.26 RoAPAC DNA Damage Response Drugs Market,
2019-2030.................................
158 Figure 13.27 Latin America DNA Damage
Response Drugs Market, 2019-2030
......................... 159 Figure 13.28
Latin America Market Dynamics ...................
..................................................
........ 160 Figure 13.29 Latin America DNA
Damage Response Drugs Market (by Country), 2019-
2030..............................................
..................................................
................................... 160 Figure
13.30 Brazil DNA Damage Response Drugs Market,
2019-2030 ......................................
162 Figure 13.31 Rest-of-Latin America DNA
Damage Response Drugs Market, 2019-2030...........
.. 163 Figure 13.32 RoW DNA Damage Response
Drugs Market, 2019-2030 ..........................
............. 164 Figure 14.1 Total Number of
Companies Profiled ...............................
..........................................
165 Figure 14.2 AbbVie Inc. Pipeline Product
Portfolio.........................................
.............................. 167 Figure 14.3
AbbVie Inc. Overall Financials, 2017-2019
..................................................
............. 168 Figure 14.4 AbbVie Inc.
Revenue (by Region), 2017-2019....................
...................................... 169 Figure
14.5 AbbVie Inc. RD Expenditure,
2017-2019.........................................
....................... 170 Figure 14.6 AbbVie
Inc. SWOT Analysis ..............................
..................................................
..... 171 Figure 14.7 AstraZeneca plc Overall
Product Portfolio ................................
................................ 173 Figure 14.8
AstraZeneca plc Pipeline Product Portfolio
..................................................
............. 174 Figure 14.9 AstraZeneca plc
Overall Financials, 2017-2019.....................
................................... 176 Figure
14.10 AstraZeneca plc Revenue (by Segment),
2017-2019 ........................................
..... 177 Figure 14.11 AstraZeneca plc Revenue
(by Region), 2017-2019 ...........................
..................... 177 Figure 14.12
AstraZeneca plc RD Expenditure, 2017-2019
..................................................
.... 178 Figure 14.13 AstraZeneca plc SWOT
Analysis .........................................
................................... 179
15
Global DNA Damage Response Drugs Market
Figure 14.14 Bayer AG Pipeline Product
Portfolio ........................................
............................... 181 Figure 14.15
Bayer AG Overall Financials, 2017-2019...........
..................................................
... 181 Figure 14.16 Bayer AG Revenue (by
Segment), 2018-2019 ..............................
......................... 182 Figure 14.17 Bayer
AG Revenue (by Region), 2017-2019
..................................................
........ 183 Figure 14.18 Bayer AG RD
Expenditure, 2017-2019............................
..................................... 184 Figure
14.19 Bayer AG SWOT Analysis ...................
..................................................
................. 185 Figure 14.20 BeiGene,
Ltd. Pipeline Product Portfolio
..................................................
............... 187 Figure 14.21 BeiGene, Ltd.
Overall Financials 2017-2019.....................
..................................... 188 Figure
14.22 BeiGene, Ltd. Revenue (by Region),
2017-2019 ........................................
............ 189 Figure 14.23 BeiGene, Ltd. RD
Expenditure, 2017-2019 ...........................
............................... 190 Figure 14.24
BeiGene, Ltd. SWOT Analysis......................
..................................................
........ 191 Figure 14.25 Clovis Oncology
Overall Product Portfolio ........................
...................................... 193 Figure
14.26 Clovis Oncology Pipeline Product
Portfolio ........................................
..................... 193 Figure 14.27 Clovis
Oncology Overall Financials, 2017-2019...........
...........................................
194 Figure 14.28 Clovis Oncology RD
Expenditure, 2017-2019 ...........................
........................... 195 Figure 14.29
Clovis Oncology SWOT Analysis....................
..................................................
...... 196 Figure 14.30 Debiopharm International
SA Pipeline Product Portfolio ...................
...................... 198 Figure 14.31
Debiopharm International SA SWOT Analysis
..................................................
...... 199 Figure 14.32 Eli Lilly Company
Pipeline Product Portfolio .......................
................................. 201 Figure
14.33 Eli Lilly Company Overall Financials,
2017-2019.........................................
........ 201 Figure 14.34 Eli Lilly Company
Revenue (by Region), 2017-2019 ...................
........................ 202 Figure 14.35 Eli
Lilly Company SWOT Analysis ...................
..................................................
.. 204 Figure 14.36 GlaxoSmithKline plc Overall
Product Portfolio ................................
........................ 206 Figure 14.37
GlaxoSmithKline plc Pipeline Product Portfolio
..................................................
..... 206 Figure 14.38 GlaxoSmithKline plc
Overall Financials, 2017-2019.....................
........................... 207 Figure 14.39
GlaxoSmithKline plc Revenue (by Segment),
2017-2019 .......................................
208 Figure 14.40 GlaxoSmithKline plc Revenue
(by Region), 2017-2019 ...........................
............... 209 Figure 14.41 GlaxoSmithKline
plc RD Expenditure, 2017-2019
................................................
209 Figure 14.42 GlaxoSmithKline plc SWOT
Analysis..........................................
............................ 210 Figure 14.43
Merck KGaA Pipeline Product Portfolio............
..................................................
..... 212 Figure 14.44 Merck KGaA Overall
Financials, 2017-2019 ............................
............................... 213
16
Global DNA Damage Response Drugs Market
Figure 14.45 Merck KGaA Revenue (by Segment),
2017-2019.........................................
.......... 213 Figure 14.46 Merck KGaA Revenue
(by Region), 2017-2019............................
.......................... 214 Figure 14.47
Merck KGaA RD Expenditure, 2017-2019............
................................................
215 Figure 14.48 Merck KGaA SWOT Analysis
..................................................
............................... 216 Figure 14.49
NMS Group S.p.A Pipeline Product Portfolio
..................................................
........ 218 Figure 14.50 NMS Group S.p.A SWOT
Analysis .........................................
................................ 219 Figure
14.51 Onxeo SA Pipeline Product Portfolio
..................................................
.................... 221 Figure 14.52 Onxeo SA
Overall Financials, 2017-2019 ....................
...........................................
222 Figure 14.53 Onxeo SA Revenue (by Segment),
2017-2019.........................................
.............. 223 Figure 14.54 Onxeo SA
Revenue (by Region), 2017.........................
..........................................
223 Figure 14.55 Onxeo SA Revenue (by Region),
2018-2019.........................................
................. 224 Figure 14.56 Onxeo SA RD
Expenditure (by Region), 2018-2019
............................................ 224
Figure 14.57 Onxeo SA SWOT Analysis
..................................................
................................... 225 Figure
14.58 Pfizer Inc. Overall Product Portfolio
..................................................
...................... 227 Figure 14.59 Pfizer
Inc. Pipeline Product Portfolio
..................................................
..................... 227 Figure 14.60 Pfizer
Inc. Overall Financials, 2017-2019...............
.................................................
228 Figure 14.61 Pfizer Inc. Revenue (by
Segment), 2017-2019 ..............................
......................... 229 Figure 14.62
Pfizer Inc. Revenue Split (by Biopharma
Segment), 2017-2019 .............................
230 Figure 14.63 Pfizer Inc. Revenue (by
Region), 2017-2019 ...............................
........................... 231 Figure 14.64
Pfizer Inc. RD Expenditure, 2017-2019
..................................................
.............. 232 Figure 14.65 Pfizer Inc.
SWOT Analysis.....................................
.................................................
233 Figure 14.66 Repare Therapeutics Pipeline
Product Portfolio ................................
..................... 235 Figure 14.67 Repare
Therapeutics SWOT Analysis ......................
..............................................
236 Figure 14.68 Sierra Oncology, Inc. Pipeline
Product Portfolio.................................
..................... 238 Figure 14.69 Sierra
Oncology, Inc. Overall Financials, 2017-2019
..............................................
239 Figure 14.70 Sierra Oncology, Inc. RD
Expenditure, 2017-2019............................
................... 240 Figure 14.71 Sierra
Oncology, Inc. SWOT Analysis ....................
................................................
241 Figure 14.72 Zentalis Pharmaceuticals, LLC
Pipeline Product Portfolio........................
............... 243 Figure 14.73 Zentalis
Pharmaceuticals, LLC SWOT Analysis
..................................................
... 244
17
Global DNA Damage Response Drugs Market
List of Tables Table 4.1 Approved DNA Damage
Response Drugs, May 2020 .........................
........................... 45 Table 6.1 Impact
Analysis of Market Drivers........................
..................................................
......... 61 Table 6.2 Impact Analysis of Market
Restraints .......................................
....................................... 62 Table
6.3 Comparison of RD Expenditure of Major
Companies in Global DNA Damage Response Drugs
Market, Million, 2019 and 2018
..................................................
............ 65 Table 8.1 Cancer Types Treated
with DNA Damage Response Drugs ...................
....................... 80 Table 11.1 Pipeline
of PARP Inhibitors in the Global DNA Damage
Response Drugs Market...... 106 Table 11.2
Pipeline of PARP Inhibitors in the Global DNA
Damage Response Drugs Market...... 106 Table
11.3 Pipeline of WEE1 Kinase Inhibitors in the
Global DNA Damage Response Drugs
Market............................................
..................................................
.................................. 107 Table
11.4 Pipeline of ATR Kinase Inhibitors in the
Global DNA Damage Response Drugs
Market............................................
..................................................
.................................. 108 Table
11.5 Pipeline of ATR Kinase Inhibitors in the
Global DNA Damage Response Drugs
Market............................................
..................................................
.................................. 108 Table
11.6 Pipeline of Aurora B Kinase Inhibitor in
the Global DNA Damage Response Drugs Market
..................................................
..................................................
................. 109 Table 11.7 Pipeline of
DNA-PK Inhibitor in the Global DNA Damage
Response Drugs Market............................
..................................................
..................................................
110 Table 11.8 Pipeline of DNA-PK Inhibitor in
the Global DNA Damage Response Drugs Market.......
..................................................
..................................................
..................... 110 Table 11.9 Pipeline of
Other Inhibitors in the Global DNA Damage
Response Drugs Market....... 111 Table 11.10
Pipeline of Other Inhibitors in the Global DNA
Damage Response Drugs Market......................
..................................................
..................................................
...... 111 Table 12.1 Marketed DNA Damage
Response (DDR) Drugs for Ovarian Cancer
........................ 115 Table 12.2 DNA
Damage Response (DDR) Drugs for Ovarian Cancer
Pipeline Products .......... 117 Table 12.3
Marketed DNA Damage Response (DDR) Drugs for
Breast Cancer ..........................
120 Table 12.4 DNA Damage Response (DDR) Drugs
for Breast Cancer Pipeline Products ............
120 Table 12.5 Marketed DNA Damage Response
(DDR) Drugs for Pancreatic Cancer.................
... 122 Table 12.6 DNA Damage Response (DDR)
Drugs for Pancreatic Cancer Pipeline Products
...... 123
18
Global DNA Damage Response Drugs Market
Table 12.7 Marketed DNA Damage Response (DDR)
Drugs for Prostate Cancer .......................
124 Table 12.8 DNA Damage Response (DDR) Drugs
for Prostate Cancer Pipeline Products..........
125
19
Global DNA Damage Response Drugs Market
BIS Research Offerings We are on a mission to
harness the potential of disruptive technologies
to make businesses thrive in todays digital
age. We have a vision to be a leading and a
preferred knowledge partner for corporates and
institutions worldwide and assist them with
market intelligence in the area of emerging
technologies, advisories, and other innovative
solutions.
Know More
Know More
Know More
Know More
20
Global DNA Damage Response Drugs Market
Disclaimer BIS Research provides valuable market
intelligence to an exclusive group of customers
in response to orders. The report is licensed
for the customer's internal use only and is
subject to restrictions set henceforth. This
document and its contents are confidential and
may not be further distributed, published or
reproduced, in whole or in part, by any medium or
in any form for any purpose, without the express
written consent of BIS Research. Customer will
not disclose the contents of the report, whether
directly in any media or indirectly through
incorporation in a database, marketing list,
report or otherwise, or use or permit the use of
Information to generate any statistical or other
information that is or will be provided to third
parties or voluntarily produce Information in
legal proceedings. Market reports are based on
expectations, estimates and projections as of the
date such information is available. Any
recommendation contained in this report may not
be suitable for all investors or businesses. The
market conclusions drawn are necessarily based
upon a number of estimates and assumptions that,
while considered reasonable by BIS Research as of
the date of such statements, are inherently
subject to market fluctuations and business,
economic and competitive uncertainties and
contingencies
For more details regarding permission, please
contact us Email sales_at_bisresearch.com Tel 1
510 404 8135
21
Global DNA Damage Response Drugs Market
BIS RESEARCH INC. 39111 Paseo Padre PKWY, Suite
313 Fremont, CA 94538 -1686 E-mail
info_at_bisresearch.com Call Us 1-510-404-8135
Global Delivery Center Tower B First Floor,
Tapasya Corporate Heights, Greater Noida
Expressway, Sector 126, Noida, U.P., 201303,
India Tel [phone]
All rights reserved at BIS Research 21